NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









BrainEver

BrainEver

Private
ParisHealthcare & Life Scienceshttps://brainever.fr/

Last Round

Grant

Jun 8, 2022

Total Funding Raised

$27.53M

Company Overview

BrainEver is a biotechnology company that develops innovative therapies for neurodegenerative diseases using homeoprotein-based treatments.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologyneurodegenerative diseasehomeoprotein therapyamyotrophic lateral sclerosisALSdrug developmentbiopharmaprotein-based therapyclinical trialsParkinson's diseaseretinal diseaseneuroscience researchbiotech startupprecision medicinedrug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BrainEver Comparables

Compare BrainEver with similar companies based on industry and business-model similarity.

BrainEver comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
ProJenX, Inc.
80%
AcuraStem
78%
Aclipse Therapeutics
76%

BrainEver Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJun 8, 2022
Series ANov 23, 2020

Key People

Founding team and executive leadership

Alain Prochiantz

Co-founder & Chief Scientific Officer

Founding Team

Bernard Gilly

CEO

Executive Team

Catherine Pletan

Acting Chief Operating Officer Head of Operations

Executive Team

BrainEver Investors

Notable investors and investment history

BrainEver investors
InvestorRounds
European Innovation Council FundGrant
Turenne GroupeSeries A
iBionextSeries A
BpifranceSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 22, 2026

    Grew 29% QoQ, from 21 to 27 employees.

  • Jan 16, 2025

    Grew 20% QoQ from 15 to 18 employees.

BrainEver Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BrainEver Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BrainEver's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range25
Year Founded2016
Last FundingJun 8, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.